Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Anakinra
See also Interleukins
General information
Anakinra is an interleukin-1 receptor antagonist. It has been used to treat rheumatoid arthritis [ , ]. It has been tried in graft-versus-host disease, but without success [ ]. According to published trial data, moderate injection site reactions were the primary adverse effect and required treatment withdrawal in under 5% of patients. An erythematous rash was seldom observed. Although a few patients have developed antibodies to anakinra, these have not so far been associated with lack of efficacy or allergic skin reactions.
Drug studies
Placebo-controlled studies
In 1414 patients with rheumatoid arthritis of varying severity and various co-morbid conditions randomized to receive anakinra 100 mg/day (n = 1116) or placebo (n = 283) the rate of serious adverse events and malignancies after 6 months of treatment was similar in the two groups [ ]. Serious infectious episodes occurred more often in the treated group (2.1%) than in the placebo group (0.4%), but the difference was not statistically significant. Unusual or opportunistic infections were not identified. Mild-to-moderate injection-site reactions were the most commonly reported adverse effects attributed to anakinra (73%).
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here